Part 4: Myelodysplastic syndromes-Treatment of low-risk patients with the 5q deletion

被引：1

作者：

Meira Magalhaes, Silvia Maria ^{[1
]}

Pereira Velloso, Elvira Deolinda Rodrigues ^{[2
,3
]}

Buzzini, Renata ^{[4
]}

Bernardo, Wanderley Marques ^{[2
,4
]}

机构：

[1] Univ Fed Ceara HUWC UFC, Hosp Univ Walter Cantidio, Fortaleza, Ceara, Brazil

[2] Univ Sao Paulo HC FMUSP, Hosp Clin, Fac Med, Sao Paulo, SP, Brazil

[3] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil

[4] Assoc Med Brasileira AMB, Sao Paulo, SP, Brazil

来源：

HEMATOLOGY TRANSFUSION AND CELL THERAPY | 2018年 / 40卷 / 03期

关键词：

D O I：

10.1016/j.htct.2018.05.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：274 / 277

页数：4

共 18 条

[1]

[Anonymous], 2021, PLYMOUTH M

[2] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[3] TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes [J].

Belickova, Monika ;

Vesela, Jitka ;

Jonasova, Anna ;

Pejsova, Barbora ;

Votavova, Hana ;

Merkerova, Michaela Dostalova ;

Zemanova, Zuzana ;

Brezinova, Jana ;

Mikulenkova, Dana ;

Lauermannova, Marie ;

Valka, Jan ;

Michalova, Kyra ;

Neuwirtova, Radana ;

Cermak, Jaroslav .

ONCOTARGET, 2016, 7 (24) :36266-36279

[4] Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Fenaux, P. ;

Haase, D. ;

Sanz, G. F. ;

Santini, V. ;

Buske, C. .

ANNALS OF ONCOLOGY, 2014, 25 :57-69

[5] A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q [J].

Fenaux, Pierre ;

Giagounidis, Aristoteles ;

Selleslag, Dominik ;

Beyne-Rauzy, Odile ;

Mufti, Ghulam ;

Mittelman, Moshe ;

Muus, Petra ;

Boekhorst, Peter Te ;

Sanz, Guillermo ;

del Canizo, Consuelo ;

Guerci-Bresler, Agnes ;

Nilsson, Lars ;

Platzbecker, Uwe ;

Luebbert, Michael ;

Quesnel, Bruno ;

Cazzola, Mario ;

Ganser, Arnold ;

Bowen, David ;

Schlegelberger, Brigitte ;

Aul, Carlo ;

Knight, Robert ;

Francis, John ;

Fu, Tommy ;

Hellstrom-Lindberg, Eva .

BLOOD, 2011, 118 (14) :3765-3776

[6]

Goldet Gabrielle, 2013, J Evid Based Med, V6, P50, DOI 10.1111/jebm.12018

[7] TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression [J].

Jaedersten, Martin ;

Saft, Leonie ;

Smith, Alexander ;

Kulasekararaj, Austin ;

Pomplun, Sabine ;

Goehring, Gudrun ;

Hedlund, Anette ;

Hast, Robert ;

Schlegelberger, Brigitte ;

Porwit, Anna ;

Hellstrom-Lindberg, Eva ;

Mufti, Ghulam J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :1971-1979

[8] TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis [J].

Kulasekararaj, Austin G. ;

Smith, Alexander E. ;

Mian, Syed A. ;

Mohamedali, Azim M. ;

Krishnamurthy, Pramila ;

Lea, Nicholas C. ;

Gaeken, Joop ;

Pennaneach, Coralie ;

Ireland, Robin ;

Czepulkowski, Barbara ;

Pomplun, Sabine ;

Marsh, Judith C. ;

Mufti, Ghulam J. .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (05) :660-672

[9] Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis [J].

Lian, Xin-yue ;

Zhang, Zhi-hui ;

Deng, Zhao-qun ;

He, Pin-fang ;

Yao, Dong-ming ;

Xu, Zi-jun ;

Wen, Xiang-mei ;

Yang, Lei ;

Lin, Jiang ;

Qian, Jun .

PLOS ONE, 2016, 11 (11)

[10] Efficacy of lenalidomide in myelodysplastic syndromes [J].

List, A ;

Kurtin, S ;

Roe, DJ ;

Buresh, A ;

Mahadevan, D ;

Fuchs, D ;

Rimsza, L ;

Heaton, R ;

Knight, R ;

Zeldis, JB .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06) :549-557

← 1 2 →